Trump Plans Federal AI Force and AI Czar 
JPMorgan Names Lavatelli Japan Chief in Leadership Shake-Up 
US Stock Futures Rise as Meta Muse Fuels AI Rally 
Asian Currencies Muted as Dollar Firms Ahead of Trump-Xi Summit 
South Korea, US Discuss Warship Building Cooperation 
Novo Nordisk Weighs Direct NYSE Listing to Boost U.S. Profile 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
Gold Prices Rise as Oil Slide Eases Fed Rate Hike Fears 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
US Dollar Hits Two-Month High as Fed Rate Hike Bets Rise 
Telix to Acquire Germany’s ITM in $1.65 Billion Radiopharma Deal 
European Stocks Slip as Iran Tensions Offset Strong Eurozone Data 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Add as a preferred source on Google
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
